March Biosciences Closes Oversubscribed $28.4 Million Series A Financing

Written By Mukul Verma

HOUSTON, Oct. 23, 2024 (GLOBE NEWSWIRE) -- March Biosciences (March Bio), an emerging clinical stage biotechnology company committed to combating challenging cancers and other diseases, today announced the close of a $28.4 million oversubscribed Series A financing. Mission BioCapital and 4BIO Capital led the financing, with participation from KdT Ventures, Alexandria Venture Investments, Volnay Therapeutics, Modi Ventures, and Mansueto Investments. Existing investors TMC Venture Fund, Cancer Focus Fund, Small Ventures, and Portal Innovations also participated in the round. March Bio has raised over $51 million to date inclusive of all dilutive and non-dilutive funding.

Mukul Verma
Previous

Cancer Focus Fund Invests $5.1 Million in Starget Pharma to Support Phase 1b Clinical Trial of Novel Peptide Radioligand for Precision Cancer Therapy
Next

Biotech TV: Ross Barrett talks about a larger fund for investing in more companies, and shares technologies that excite him today.